Therma Bright: A New Approach to Skin Care

Therma Bright is a progressive medical device technology company. Currently, they're focusing on providing consumers with quality medical devices that …

Therma Bright cold sore

A medical device company with bright ideas

Therma Bright is a progressive medical device technology company. Currently, they're focusing on providing consumers with quality medical devices that address their dermatological needs.

Therma Bright has spent a significant investment in intellectual property and research and development. This is for its InterceptCS™- cold sore device, the Therozap™ insect device, and will soon invest in a novel pain relief device.  Its current product lines address cold sore treatment and prevention. It also addresses the treatment of pain, itch and inflammation related to mosquito, bee, spider, mite, and jellyfish bites or stings.

Further, the Company is in the research and development stage to develop a novel device for relief of pain. This will target pain associated with back, knee or other joint pain. Moreover, they're focused on building recurring revenue streams from its products and to incorporate intelligent technology such as AI or IoT.

Additionally, the Company holds patents pending and trademarks. These are for Therozap™ and the trademark InterceptCS™ along with regulatory approvals for its thermal therapy technology.

For more information on Therma Bright Inc. (TSX.V: THRM) please fill out the form below.

You might also like

Ivan Bebek on Where the Biggest Mining Returns May Still Lie
Metals & Mining
March 4, 2026

Ivan Bebek on Where the Biggest Mining Returns May Still Lie

Veteran mining entrepreneur Ivan Bebek believes the current gold and silver cycle may only be getting started.

This is some text inside of a div block.
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Health & Wellness
March 3, 2026

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

This is some text inside of a div block.
BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs
ETFs
March 3, 2026

BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs

In Canada, management fees for asset allocation ETFs can range from approximately 50 basis points down to 15 basis points.

This is some text inside of a div block.
Subscribe and receive the investor Info